Advanced Search:
Equity Index

POXEL.PA - POXEL

€0.52  0.027 (5.5%)

Updated: 12:01 May 5, 2024 EST

Next Session's AI Forecast

67.06%

Avg. Accuracy (AI)

€0.44

Next Week's AI Forecast

100%

Trend's Accuracy (AI)

€0.43

POXEL's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

POXEL - HISTORICAL DATA 6M

  • Last price

    €0.52

  • Daily change

    €0.027

  • Previous Close

    €0.491

  • Last Updated

    12:01 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.12 -0.06 0.59 0.77 0.12

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
1.12 4.6 3.74 4.64 3.59

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 36.41% 67.11%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
% % %

RSI METRIC

RS Hour RSI Hour RS Day RSI Day

POXEL Technical Analysis News

POXEL

Immeuble Le Sunway
259-261 Avenue Jean JaurEs
Lyon 69007
France
33 4 37 37 20 10
https://www.poxelpharma.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 15
Description

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Corporate Governance

Poxel S.A.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 4; Compensation: 10.

POXEL'S HOLDERS RANK

List of holders with stock participation in POXEL.

Holder Rank Holder Shares Date Reported % Out Value